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The last decades of translational research on cancer immunobiology are allowing the design of
profoundly innovative treatments for cancer. Nonetheless, within the scientific community, there is
raising concern on the real impact of some of these new possible therapeutic opportunities and on
how they are communicated to both health-carers and general public.
Results from randomized clinical trials, which are the gold standard for determining the efficacy
of a new treatment, are oftentimes reported as highly successful, despite some significant limitations.
A recent survey analyzed over 3,000 randomized controlled trials published in the Journal of the
American Medical Association, the Lancet, and the New England Journal of Medicine, to identify
low-value medical practices that increase costs without improving care. The authors showed that 396
out of all randomized trials regarding a wide range of medical specialties, including oncology, had not
provided results to justify the change of clinical practice as previously supposed (Herrera-Perez et al.,
2019).
Also, it is increasingly recognized that some of these trial results should be significantly downsized
prior to achieving more convincing validation in the real-world setting (Martini et al., 2020).
Lancet Oncology (The Lancet Oncology, 2018) itself published an authoritative editorial raising a
serious warning on the threat posed by the “hype” and information spread across on cancer
immunotherapy, and more in general on many new cancer therapies.
Other authors have addressed the risk of miscommunication when poorly reported responses of
single patients end up to upstage and replace real achievements based on solid background and
validated figures (Nishikawa et al., 2018). This miscommunication leads to high expectations and
strong requests from patients and their families, and often clinicians are urged to treat patients with
therapies that need a more solid validation.
The hype on some trial results can also affect the drug regulatory practice (Martini et al., 2020);
indeed, various cancer drugs have been approved without control arms only in 2019 (CG, 2020). Also
concerning is the fact that some studies did not compare new treatments with the best treatment
available (Zalcman et al., 2016; Hilal et al., 2019; IASLC, 2020). Other findings show that 67% of the
trials which led to anticancer drug marketing authorization by the Food and Drug Administration
(FDA) between 2014 and 2019 failed the criteria needed: randomized design, demonstration of
survival advantage, appropriate use of crossover, and optimal control arms (Hilal et al., 2020).
Similarly, an analysis of pivotal randomized controlled trials of new antitumoral agents approved by
the EuropeanMedicines Agency (EMA) between 2014 and 2016 concluded that almost half showed a
high risk of bias based on their design, conduct, or analysis (Naci et al., 2019).
Other groups have stigmatized that general clinical trials run by not-for-profit organizations are
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companies; indeed, 85% of the clinical trials funded by Pharmas
report positive results compared to only 50% of government-
funded trials (Ridker and Torres, 2006). Analogously, it has been
demonstrated that industry-funded trials are up to four times
more likely to draw conclusions on support of their products than
are independent trials (Sismondo, 2008; Bourgeois et al., 2010;
Lundh et al., 2017). Sadly, it has also been red-flagged how the
interactions between Pharmas and board members involved into
the definition of clinical practice guidelines can also “address” the
career of those involved (Desai et al., 2019; Boxe, 2020; Fought
et al., 2020; Mitchell et al., 2020).
As predicted (Santye, 2017), one more issue is the recent
lowering of the bar for drugs approval by the FDA that certainly
played a role to create the current situation (Sherman, 2017).
Authoritative articles have warned about the real size of what
at the moment is achievable with this approach (Dechartres et al.,
2017; Yarchoan et al., 2017). Unfortunately, as remarked in
Lancet Oncology (The Lancet Oncology, 2018), we are all
dealing with one of the biggest recent bias in medicine that
affects the potential full identification of the actual cost/benefit of
cancer immunotherapy itself.
A critical analysis of the overall results of immunotherapies
should induce some reflections (Gong et al., 2018): the broad use
of surrogate end points and the lack of (plausible) control arms
and their high fragility index restrict the real efficacy on overall
survival to a few solid tumors, that is, melanoma, non–small cell
lung cancer, and renal cell carcinoma, while concern does exist
for other common diseases including triple negative breast
cancer, small cell lung cancer, head and neck carcinoma,
malignant mesothelioma, and other urological malignancies
for which further translational-based trials and combination
therapies are eagerly required (Gong et al., 2018).
Moreover, the results of immune check point inhibitors (ICIs)
on frail patients (even with cancer considered immunotherapy-
responsive) are clearly against their use. A recent article has
shown that 49% patients hospitalized with ECOG performance
status ≥2 (which would have prevented to be enrolled in most
clinical trials of ICIs) died during their stay in hospital or within
30 days from discharge, and just 15% of patients were alive
6 months after discharge (Durbin et al., 2021).
Other authors state “Few modern, U.S. FDA-approved
immuno-oncology agents have durable survival and response
rates that are deemed significant by the American Society of
Clinical Oncology value framework” (Dechartres et al., 2017;
Ben-Aharon et al., 2018). Notwithstanding, we all are pressured
to use immunotherapy approaches. We have read “wonder drug”
up in a petition (Robson, 2016) to ask health systems to provide
these extremely expensive drugs, whereas other groups publish a
book to declare that “immunotherapy is the end of cancer” (Maio
and Minoli, 2018).
Eventually, other authors conclude that the conflict of interest
represented by the links between doctors and pharmaceutical
companies (Dechartres et al., 2017; Santye, 2017; Sherman, 2017;
Yarchoan et al., 2017; Mitchell et al., 2018) could also contribute
to explain the miscommunications on novel treatments like
immunotherapy (Kaestner et al., 2017).
The need of a more transparent collaboration between clinical
scientists and pharmaceutical companies (in particular those
involved in cancer immunotherapy) has been recently raised
to avoid biases in the conduction of the randomized clinical
trials even leading to registration by regulatory bodies
(Schirrmacher et al., 2020). With this regard, Hasting Center
Report by De Jesus-Morales and Vinay Prasad includes an article
entitled “Closed Financial Loops: When They Happen in
FIGURE 1 |Main limitations of many current clinical trials and an ideal bench–bed–bench registration process. OS: overall survival; PS: performance status; RCT:
randomized clinical trials; RWE: real-world evidence.
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Government, They’re Called Corruption; in Medicine, They’re Just
a Footnote” (De Jesus-Morales and Prasad, 2017).
Moreover, other evidences show that trial results are often either
not communicated or reported with significant delay. This occurs
despite the 2017 rule, enacted by the National Institutes of Health
(NIH) and the FDA, which clarified law expectations and penalties
for those failing to disclose promptly trial results (Piller, 2020).
Even though we believe that most clinical scientists act
according to the highest ethical standards, there is no doubt
that more transparency on the nature and entity of any sort of
conflict of interest could avoid any doubt on all the process.
Eventually, one should consider what happens with “orphan”
tumors where the urgency of better treatments clashes with the
lack of proper preclinical studies. The result of this discrepancy
leads to the exploitation of the pipelines rather than building a
strong preclinical background (Elmhirst and Brown, 2020).
Among others, this is what is happening with mesothelioma (a
pleural cancer mainly due to asbestos exposure) where after a long
period of time when tremelimumab and pembrolizumab were
hailed as a revolution for this tumor on the basis of earlier small
studies (“the syrup that melts tumors” (Fondazione Buzzi Unicem,
2016), until the results of randomized clinical trials and real-world
evidence with overall survival as end points have demonstrated
their inefficacy (Maio et al., 2017; Popat et al., 2020) and pointed
out how the outcome was rather biased by performance status real-
world evidence (Ahmadzada et al., 2020; Lau et al., 2020).
More recently, a combination of ICIs has been demonstrated
to top standard chemotherapy for mesothelioma. However, the
comparison control arm was not the best treatment known
(Zalcman et al., 2016; IASLC, 2020). If one compares the
survival of ICIs with the best treatment, this latter is still superior.
Likewise, other empirical approaches without neither
background nor solid study design and control arm have been
proposed to be the new frontline therapy for this orphan disease
(Barbarino et al., 2020; de Gooijer and Burgers, 2020).
Therefore, the lack of a strong tumor-specific rationale, the
characteristic of the patient enrolled (most of them in very good
performance status) and the suboptimal end points and control arms
together with high fragility index of many of these trial (Bomze et al.,
2020; Bomze and Meirson, 2019) influence the success of the trials
and may lead to the registration of therapies despite uncertain
efficacy to justify their toxicity and exorbitant economic costs
(Schirrmacher et al., 2020). Moreover, several cautionary tales
suggest the results for clinical trials should not be set in stone
before being validated by everyday performance by real-world
evidence (Van Cutsem, 1999; Muhsin et al., 2003; Correale et al.,
2016; Proto et al., 2019; Martini et al., 2020). We hope that a more
science-based approval process will inspire the approval of new
immunotherapies for cancer (Figure 1) and create the conditions for
an even synergism between the need of results quality and validation
and the registration of new drugs for cancer immuneotherapy.
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